Revelation Biosciences Inc (NASDAQ:REVB) Reports Wider-Than-Expected Q2 2025 Loss, Extends Cash Runway to Year-End

Revelation Biosciences Reports Q2 2025 Earnings: Wider-Than-Expected Loss, Cash Runway Extends Through Year-End

Revelation Biosciences Inc (NASDAQ:REVB) reported its financial results for the second quarter of 2025, posting a net loss per share of $(7.01), significantly wider than the analyst consensus estimate of $(4.54). The company reported no revenue, in line with expectations, as it remains a pre-revenue clinical-stage biotech firm focused on developing immunologic-based therapies.

Key Financial Takeaways

• Net Loss: The company reported a net loss of $2.4 million for Q2 2025, compared to a net loss of $8.4 million in the same period last year.
• Cash Position: As of June 30, 2025, Revelation had $5.2 million in cash and cash equivalents, down from $6.5 million at the end of 2024. Management stated that current funds are expected to support operations through December 2025.
• Operating Expenses: Total operating expenses for the quarter were $2.46 million, a slight decrease from $2.52 million in Q2 2024.

Market Reaction

Following the earnings release, Revelation’s stock saw a pre-market decline of ~5.1%, reflecting investor disappointment over the larger-than-expected loss. Over the past month, shares have declined nearly 9.7%, underperforming broader market trends.

Clinical and Corporate Updates

• PRIME Phase 1b Study: The company completed patient dosing in its Phase 1b trial of Gemini, its lead therapeutic candidate, for chronic kidney disease (CKD). Data from this study is expected later this quarter.
• Financing: In May 2025, Revelation raised $4 million in a public offering, providing additional liquidity.
• Regulatory Plans: The company anticipates engaging with the FDA later this year to discuss further clinical development of Gemini.

Looking Ahead

Analysts currently project a full-year 2025 EPS of $(14.48), with no revenue expected. For Q3 2025, the consensus EPS estimate stands at $(3.78). Revelation did not provide formal guidance in its earnings release, but its cash runway suggests it will need additional funding to advance its clinical programs beyond the end of the year.

For more detailed earnings estimates and historical performance, visit Revelation Biosciences' earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.